Amneal wins FDA approval for additional iohexol injection strengths and vial sizes
AMRX•FDA approval expands Amneal's iohexol portfolio
Amneal won FDA clearance for new strengths and vial sizes of iohexol injection, expanding its generic OMNIPAQUE-referenced contrast portfolio.
- Launch targeted for Q3 2026.
- The company expects broader coverage of U.S. demand across key hospital and imaging-center presentations.
- IQVIA estimates U.S. annual iohexol injection sales at about $706 million for the 12 months ended May 2026.
Related News
Stellantis Says MoU Signed Between Opel Automobile GmbH And AGM Holding Company To Localise First Engine Production in Algeria
STLA•
Wyndham Hotels & Resorts Inc <WH.N>: Morgan Stanley raises target price to $93.00 from $89.00
WH•
